Pregnancy impacts the functioning of the thyroid gland profoundly and is associated with a 10%-40% increase in the size of the gland (iodine-replete areas show greater increase), a 50% increase in the production of thyroxine (T4) and triiodothyronine (T3), and a 50% increase in the daily requirement of iodine. These physiological changes can render a pregnant, iodine-deficient, euthyroid woman in the first trimester hypothyroid during the later stages of pregnancy.
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Human chorionic gonadotropin (hCG), secreted by the placenta, also impacts thyroid function because it simulates thyroid-stimulating hormone (TSH) activity in vivo, thereby suppressing its secretion.
1,2
Evidence suggests that throughout pregnancy, TSH values are lower than in the pre-pregnant state, and may even be below the classical lower limit of 0.4 mIU/L. 3, 4 hCG concentrations are increased to a greater extent in multiple pregnancies; therefore, the downward shift is even more significant in these cases. Since the levels of hCG decrease as the pregnancy increases, the levels of TSH follow the reverse trend.
Therefore, trimester-specific cut-off values of TSH should be used for diagnosis of hyper-or hypothyroidism during pregnancy, rather than Studies also report a significant decrease in the levels of free T4
with the progression of pregnancy. 3, 6, 7 Measurements of free T4 are complicated by the increased levels of thyroxine-binding globulin and decreased levels of albumin during pregnancy, which make the immunoassays unreliable. 8, 9 The best method to assess free T4 during pregnancy is to measure T4 in the dialysate/ultrafiltrate of the serum samples employing on-line extraction/liquid chromatography or tandem mass spectrometry. 5 However, if these methods are unavailable, the clinician can employ any available technique, with the knowledge of its shortcomings. Notably, serum TSH is a superior indicator of thyroid function in pregnancy.
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HYPOTHYROIDISM
Primary maternal hypothyroidism is defined as the increase in serum Several US studies reported a 2%-3% incidence of hypothyroidism amongst healthy, non-pregnant women of child-bearing age.
11,12
Around 0.3%-0.5% of these women are classified in the OH group, and the rest in the SCH category. These values are likely to higher in countries with iodine deficiency.
Pregnancy is a state with increased thyroid hormone requirements. As a result, roughly 50%-85% of previously hypothyroid women (on treatment) need to increase their dose of l-thyroxine postconception. [15] [16] [17] This adjustment should be made as soon as possible after the pregnancy is confirmed, and an increment in dose of 25%-30% is usually required. This increment can achieved either by increasing the dosage as a whole or by taking two extra tablets of the previous treatment per week. Follow up should be done in the same way as for newly diagnosed OH or SCH cases during pregnancy. After delivery, the dose of l-thyroxine should be decreased to the preconception dose and serum TSH levels checked around 6 weeks postpartum.
Although if untreated overt hypothyroidism is associated with adverse maternal and fetal outcomes, no data suggest that adequately treated patients have increased morbidity or mortality. Therefore, there is no indication for additional testing or surveillance in such patients.
HYPERTHYROIDISM
Hyperthyroidism can likewise complicate pregnancies, although its incidence is lesser than hypothyroidism. Gestational hyperthyroidism is the most common cause, accounting for 1%-3% cases of hyperthyroidism, and is characterized by "transient hyperthyroidism, limited to the first half of pregnancy characterized by elevated fT4 or adjusted T4 and suppressed or undetectable serum TSH, in the absence of serum markers of thyroid autoimmunity". [18] [19] [20] It is thought to occur because of high hCG levels and may be associated with hyperemesis gravidarum, multiple gestation, hydatidiform mole, or choriocarcinoma. 21, 22 Grave's disease is the second most common cause of hyperthyroidism, accounting for 0.1%-1% cases, 23 and might be diagnosed for the first time during pregnancy or be present as a recurrent episode. Other causes include toxic multinodular goitre, toxic adenoma, and factitious thyrotoxicosis.
The differentiation between gestational hyperthyroidism and Grave's disease can be made on the basis of clinical signs of Grave's disease, such as goiter and endocrine ophthalmopathy. If in doubt, the determination of TSH receptor antibody is indicated as it will be absent in gestational hyperthyroidism and present in Grave's disease. There is inconclusive evidence for the use of thyroid ultrasound for differentiation between gestational hyperthyroidism and Grave's disease in pregnancy, whereas the use of radioactive iodine uptake/scanning is contraindicated. Unlike gestational hyperthyroidism, that due to Grave's disease requires treatment with antithyroid drugs and the obstetric and medical complications are directly related to the control of hyperthyroidism and the duration of euthyroidism during pregnancy. [25] [26] [27] [28] Poor control is associated with an increased incidence of miscarriages, preeclampsia, prematurity, low birth weight, intrauterine growth restriction, stillbirth, thyroid storm, and maternal congestive heart failure.
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Propylthiouracial is the preferred treatment in the first trimester, with a switch to carbimazole/methimazole for subsequent trimesters. This approach is because propylthiouracial has not been associated with the teratogenic effects that have been associated with carbimazole/ methimazole, but it is associated with risk of hepatotoxicity, which may occur at any time during treatment. Beta blockers, such as propranolol, are used to control the hypermetabolic symptoms, with dose titration according to the clinical symptoms. These drugs can usually be safely withdrawn within 2-6 weeks since prolonged use has been associated with intrauterine growth restriction, fetal bradycardia, and fetal hypoglycemia.
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All antithyroid drugs cross the placenta and therefore the aim is to maintain the free T4 values at or just above the upper limit of normal using the smallest possible dose so as to avoid harmful effects on the fetus. The free T4 values should be monitored every 2-6 weeks.
Thyroidectomies are rarely indicated (allergy/contraindication to antithyroid drugs, non-compliance, large dose required) and should be performed in the second trimester, if needed.
In all cases of hyperthyroidism, determination of serum TSH receptor antibody around 24-28 weeks is advised to facilitate detection of pregnancies at risk of fetal hyperthyroidism. A value above three times the upper limit of normal is an indication for the close follow up of the fetus. Follow up with serial ultrasounds can be performed in such cases. However, cordocentesis should only be done if fetal goiter is detected in women receiving antithyroid drugs, to determine whether the fetus is hyper-or hypothyroid. This is because cordocentesis is associated with both fetal morbidity and mortality. 31, 32 Breastfeeding is safe in mothers taking antithyroid in moderated doses. Methimizole can be given in doses up to 20-30 mg/day, whereas propylthiouracial is safe up to doses of 300 mg/day. Both should be administered following the feed in divided doses.
REQUIREMENT OF IODINE
Iodine requirement is increased during pregnancy because of increased thyroid hormone production, increased renal iodine excretion, and fetal iodine requirements. 33 Women who had adequate iodine intake before and during pregnancy have adequate iodine stores and therefore have no difficulty in adapting to the increased demands. 34 However, inadequate stores are gradually depleted dur- | 349
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Therefore, women with iodine deficiency should receive iodine supplementation as it decreases the chances of the aforementioned adverse outcomes. Supplementation should be instituted early because much fetal development occurs in the first trimester. As per WHO guidelines, the recommended total dietary intake of iodine is 250 μg/day. 36 At the same time, excessive consumption of iodine should also be avoided due to the potential of fetal hypothyroidism (Wolff-Chaikoff effect) and guidelines advise against exceeding an intake of 500-1100 μg/day.
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POSTPARTUM
Postpartum thyroiditis is the occurrence, in the first postpartum year, of thyroid dysfunction in previously euthyroid women. 39 It is found in about 8.1% women and this prevalence varies from one region to another. 40 Classically, postpartum thyroiditis is characterized by transient thyrotoxicosis followed by transient hypothyroidism, with
an eventual return to a euthyroid state by the end of the first postpartum year. 41 The initial thyrotoxic phase usually occurs 3 months after delivery and is characterized by nervousness, irritability, and palpitations. However, these symptoms are mostly not attended to and attributed falsely to anxiety neurosis occurring especially after the birth of a female child. This phase is controlled with beta blockers, such as propranolol, and does not require antithyroid treat- Postpartum thyroiditis is considered an exacerbation of an underlying autoimmune thyroiditis, aggravated by the immunological rebound that follows the partial immunosuppression of pregnancy.
42,43
It is associated with the presence of antithyroid antibodies in the first trimester, with increased titers conferring an increased likelihood.
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Women with other autoimmune disorders, such as type 1 diabetes 45, 46 and systemic lupus erythematosus, 47 also have an increased risk. There is a 70% recurrence rate of postpartum thyroiditis in subsequent pregnancies amongst individuals who recover. 48 Spontaneous pregnancy losses and miscarriages occur in around 17%-31% pregnancies 49 and are a significant burden to the parents, both emotionally and because of its propensity to cause bleeding, 
OTHER THYROID PROBLEMS IN PREGNANCY
Thyroid nodules and thyroid cancer can present in pregnancy, posing many added challenges to both the clinician and the mother.
Prevalence of nodules and cancer was roughly between 3% and Radioiodine uptake studies are contraindicated in pregnancy 55, 56 and should never be performed. Surgery in such patients should be deferred until postpartum in all patients with benign disease or well differentiated malignant disease unless the nodules show rapid growth, severe compressive symptoms develop, or a large primary tumor or extensive lymph node metastasis is present. 5, 57, 58 This is because several studies investigating the adverse effects of pregnancy on the prognosis of benign and well differentiated thyroid cancer did not find an association. [57] [58] [59] [60] [61] [62] However, if surgery is deferred, these women should undergo follow-up ultrasounds every trimester to assess for tumor growth and need for intervention. If required, surgery should be performed during the second trimester as it is safe and not associated with any increased fetal or maternal risk. is inconclusive evidence to recommend for or against the universal serum TSH screening at the first trimester visit of a pregnant woman.
